Peptide YY.
OBJECTIVE
This review discusses recent studies examining the effects of peptide YY on energy homeostasis, highlights the emerging hedonic effects of peptide YY and evaluates the therapeutic potential of the peptide YY system.


RESULTS
A role for exogenous PYY3-36 as an anorectic agent in obese humans and rodents has been established and weight loss effects demonstrated in obese rodents. New lines of evidence support a role for endogenous peptide YY in regulating energy homeostasis. The NPY-Y2 receptor mediates the anorectic actions of PYY3-36 with rodent studies implicating the hypothalamus, vagus and brainstem as key target sites. Functional imaging in humans has confirmed that PYY3-36 activates brainstem and hypothalamic regions. The greatest effects, however, were observed within the orbitofrontal cortex, a brain region involved in reward processing. Further evidence for a hedonic role for PYY3-36 is supported by rodent studies showing that PYY3-36 decreases the motivation to seek high-fat food. Rodent studies using selective Y2 agonists and strategies combining PYY3-36/Y2 agonists with other anorectic agents have revealed increased anorectic and weight-reducing effects.


CONCLUSIONS
Peptide YY plays a role in the integrative regulation of metabolism. The emerging hedonic effects of peptide YY together with the weight-reducing effects observed in obese rodents suggest that targeting the peptide YY system may offer a therapeutic strategy for obesity.
Chandarana
Keval
K
Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London, WC1E 6JJ, UK.
Batterham
Rachel
R
D000818:Animals; D004734:Energy Metabolism / Q000187:drug effects; D005247:Feeding Behavior / Q000187:drug effects; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D008954:Models, Biological; D009765:Obesity / Q000188:drug therapy; D010446:Peptide Fragments; D019894:Peptide YY / Q000097:blood / Q000737:chemistry / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use; D012201:Reward
D010446:Peptide Fragments; D019894:Peptide YY; C061785:peptide YY (3-36); C514549:peptide YY (1-36)